258 related articles for article (PubMed ID: 36627896)
1. Tackling heterogeneity in treatment-resistant breast cancer using a broad-spectrum therapeutic approach.
Lowe L; LaValley JW; Felsher DW
Cancer Drug Resist; 2022; 5(4):917-925. PubMed ID: 36627896
[TBL] [Abstract][Full Text] [Related]
2. Designing a broad-spectrum integrative approach for cancer prevention and treatment.
Block KI; Gyllenhaal C; Lowe L; Amedei A; Amin ARMR; Amin A; Aquilano K; Arbiser J; Arreola A; Arzumanyan A; Ashraf SS; Azmi AS; Benencia F; Bhakta D; Bilsland A; Bishayee A; Blain SW; Block PB; Boosani CS; Carey TE; Carnero A; Carotenuto M; Casey SC; Chakrabarti M; Chaturvedi R; Chen GZ; Chen H; Chen S; Chen YC; Choi BK; Ciriolo MR; Coley HM; Collins AR; Connell M; Crawford S; Curran CS; Dabrosin C; Damia G; Dasgupta S; DeBerardinis RJ; Decker WK; Dhawan P; Diehl AME; Dong JT; Dou QP; Drew JE; Elkord E; El-Rayes B; Feitelson MA; Felsher DW; Ferguson LR; Fimognari C; Firestone GL; Frezza C; Fujii H; Fuster MM; Generali D; Georgakilas AG; Gieseler F; Gilbertson M; Green MF; Grue B; Guha G; Halicka D; Helferich WG; Heneberg P; Hentosh P; Hirschey MD; Hofseth LJ; Holcombe RF; Honoki K; Hsu HY; Huang GS; Jensen LD; Jiang WG; Jones LW; Karpowicz PA; Keith WN; Kerkar SP; Khan GN; Khatami M; Ko YH; Kucuk O; Kulathinal RJ; Kumar NB; Kwon BS; Le A; Lea MA; Lee HY; Lichtor T; Lin LT; Locasale JW; Lokeshwar BL; Longo VD; Lyssiotis CA; MacKenzie KL; Malhotra M; Marino M; Martinez-Chantar ML; Matheu A; Maxwell C; McDonnell E; Meeker AK; Mehrmohamadi M; Mehta K; Michelotti GA; Mohammad RM; Mohammed SI; Morre DJ; Muralidhar V; Muqbil I; Murphy MP; Nagaraju GP; Nahta R; Niccolai E; Nowsheen S; Panis C; Pantano F; Parslow VR; Pawelec G; Pedersen PL; Poore B; Poudyal D; Prakash S; Prince M; Raffaghello L; Rathmell JC; Rathmell WK; Ray SK; Reichrath J; Rezazadeh S; Ribatti D; Ricciardiello L; Robey RB; Rodier F; Rupasinghe HPV; Russo GL; Ryan EP; Samadi AK; Sanchez-Garcia I; Sanders AJ; Santini D; Sarkar M; Sasada T; Saxena NK; Shackelford RE; Shantha Kumara HMC; Sharma D; Shin DM; Sidransky D; Siegelin MD; Signori E; Singh N; Sivanand S; Sliva D; Smythe C; Spagnuolo C; Stafforini DM; Stagg J; Subbarayan PR; Sundin T; Talib WH; Thompson SK; Tran PT; Ungefroren H; Vander Heiden MG; Venkateswaran V; Vinay DS; Vlachostergios PJ; Wang Z; Wellen KE; Whelan RL; Yang ES; Yang H; Yang X; Yaswen P; Yedjou C; Yin X; Zhu J; Zollo M
Semin Cancer Biol; 2015 Dec; 35 Suppl(Suppl):S276-S304. PubMed ID: 26590477
[TBL] [Abstract][Full Text] [Related]
3. Overview of resistance to systemic therapy in patients with breast cancer.
Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN
Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229
[TBL] [Abstract][Full Text] [Related]
4. Broad targeting of angiogenesis for cancer prevention and therapy.
Wang Z; Dabrosin C; Yin X; Fuster MM; Arreola A; Rathmell WK; Generali D; Nagaraju GP; El-Rayes B; Ribatti D; Chen YC; Honoki K; Fujii H; Georgakilas AG; Nowsheen S; Amedei A; Niccolai E; Amin A; Ashraf SS; Helferich B; Yang X; Guha G; Bhakta D; Ciriolo MR; Aquilano K; Chen S; Halicka D; Mohammed SI; Azmi AS; Bilsland A; Keith WN; Jensen LD
Semin Cancer Biol; 2015 Dec; 35 Suppl(Suppl):S224-S243. PubMed ID: 25600295
[TBL] [Abstract][Full Text] [Related]
5. A broad-spectrum integrative design for cancer prevention and therapy: The challenge ahead.
Bishayee A; Block K
Semin Cancer Biol; 2015 Dec; 35 Suppl():S1-S4. PubMed ID: 26260004
[TBL] [Abstract][Full Text] [Related]
6. Heterogeneity of Tumors in Breast Cancer: Implications and Prospects for Prognosis and Therapeutics.
Tuasha N; Petros B
Scientifica (Cairo); 2020; 2020():4736091. PubMed ID: 33133722
[TBL] [Abstract][Full Text] [Related]
7. Natural products as drug candidates for breast cancer (Review).
Telang NT
Oncol Lett; 2023 Aug; 26(2):349. PubMed ID: 37427344
[TBL] [Abstract][Full Text] [Related]
8. Circulating tumor cells in breast cancer: functional heterogeneity, pathogenetic and clinical aspects.
Cherdyntseva NV; Litviakov NV; Denisov EV; Gervas PA; Cherdyntsev ES
Exp Oncol; 2017 Mar; 39(1):2-11. PubMed ID: 28361862
[TBL] [Abstract][Full Text] [Related]
9. Tackling intra- and inter-tumor heterogeneity to combat triple negative breast cancer.
Wright N; Rida PCG; Aneja R
Front Biosci (Landmark Ed); 2017 Jun; 22(9):1549-1580. PubMed ID: 28410132
[TBL] [Abstract][Full Text] [Related]
10. Clusterin and chemoresistance.
Djeu JY; Wei S
Adv Cancer Res; 2009; 105():77-92. PubMed ID: 19879424
[TBL] [Abstract][Full Text] [Related]
11. Molecular targets and therapeutics in chemoresistance of triple-negative breast cancer.
Nath A; Mitra S; Mistry T; Pal R; Nasare VD
Med Oncol; 2021 Nov; 39(1):14. PubMed ID: 34812991
[TBL] [Abstract][Full Text] [Related]
12. Immunotherapy for triple-negative breast cancer: Existing challenges and exciting prospects.
Jia H; Truica CI; Wang B; Wang Y; Ren X; Harvey HA; Song J; Yang JM
Drug Resist Updat; 2017 May; 32():1-15. PubMed ID: 29145974
[TBL] [Abstract][Full Text] [Related]
13. Prediction of broad spectrum resistance of tumors towards anticancer drugs.
Efferth T; Konkimalla VB; Wang YF; Sauerbrey A; Meinhardt S; Zintl F; Mattern J; Volm M
Clin Cancer Res; 2008 Apr; 14(8):2405-12. PubMed ID: 18413831
[TBL] [Abstract][Full Text] [Related]
14. Chromosomal Instability as Enabling Feature and Central Hallmark of Breast Cancer.
Castellanos G; Valbuena DS; Pérez E; Villegas VE; Rondón-Lagos M
Breast Cancer (Dove Med Press); 2023; 15():189-211. PubMed ID: 36923397
[TBL] [Abstract][Full Text] [Related]
15. Single-cell RNA sequencing in breast cancer: Understanding tumor heterogeneity and paving roads to individualized therapy.
Ding S; Chen X; Shen K
Cancer Commun (Lond); 2020 Aug; 40(8):329-344. PubMed ID: 32654419
[TBL] [Abstract][Full Text] [Related]
16. Heterogeneity of triple negative breast cancer: Current advances in subtyping and treatment implications.
Asleh K; Riaz N; Nielsen TO
J Exp Clin Cancer Res; 2022 Sep; 41(1):265. PubMed ID: 36050786
[TBL] [Abstract][Full Text] [Related]
17. Curcumin as an Enhancer of Therapeutic Efficiency of Chemotherapy Drugs in Breast Cancer.
Farghadani R; Naidu R
Int J Mol Sci; 2022 Feb; 23(4):. PubMed ID: 35216255
[TBL] [Abstract][Full Text] [Related]
18. Towards a targeted multi-drug delivery approach to improve therapeutic efficacy in breast cancer.
Wang B; Rosano JM; Cheheltani R; Achary MP; Kiani MF
Expert Opin Drug Deliv; 2010 Oct; 7(10):1159-73. PubMed ID: 20738211
[TBL] [Abstract][Full Text] [Related]
19. Chemoresistance mechanisms of breast cancer and their countermeasures.
Ji X; Lu Y; Tian H; Meng X; Wei M; Cho WC
Biomed Pharmacother; 2019 Jun; 114():108800. PubMed ID: 30921705
[TBL] [Abstract][Full Text] [Related]
20. In Situ Metabolic Characterisation of Breast Cancer and Its Potential Impact on Therapy.
Petővári G; Dankó T; Tőkés AM; Vetlényi E; Krencz I; Raffay R; Hajdu M; Sztankovics D; Németh K; Vellai-Takács K; Jeney A; Kulka J; Sebestyén A
Cancers (Basel); 2020 Sep; 12(9):. PubMed ID: 32899149
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
